Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B′ strains by recombinant Mycobacterium bovis BCG-based candidate vaccine
Autor: | Satoshi Naganawa, Shinji Haga, Tetsuya Nakasatomi, Kenji Someya, Yoshitomo Chujoh, Hitomi Yoshizaki, Kazuhiro Matsuo, Hiroshi Yoshikura, Mitsuo Honda, Yukari Okamoto, Shudo Yamazaki, Akihiro Yamazaki |
---|---|
Rok vydání: | 2001 |
Předmět: |
Genetic Vectors
Guinea Pigs Molecular Sequence Data HIV Infections HIV Antibodies HIV Envelope Protein gp120 Biology Epitope Virus law.invention Microbiology Epitopes Immune system Neutralization Tests law Animals Humans Amino Acid Sequence HIV vaccine Neutralizing antibody AIDS Vaccines Vaccines Synthetic Mycobacterium bovis General Veterinary General Immunology and Microbiology Public Health Environmental and Occupational Health Thailand biology.organism_classification Virology Peptide Fragments Infectious Diseases BCG Vaccine HIV-1 Recombinant DNA biology.protein Molecular Medicine Antibody |
Zdroj: | Vaccine. 20:797-804 |
ISSN: | 0264-410X |
Popis: | The recombinant Mycobacterium bovis BCG (rBCG) vector-based vaccine secreting the V3 principal neutralizing epitope of human immunodeficiency virus type 1 (HIV-1) Japanese strain was reported to induce both humoral and cellular immune responses effectively [Proc. Natl. Acad. Sci. USA. 92 (1995) 10693]. The antigen-secreting rBCG system was applied to the V3 epitope of clade E HIV-1 in this study. The V3 sequence of 19 amino acids (aa) and 15aa fused with mycobacterial α-antigen was not secreted while 12aa and 11aa sequences were successfully secreted from BCG cells. Serum IgG from guinea pig which was immunized with 12aa epitope-secreting recombinant BCG neutralized the WHO reference strain as well as primary field isolates of clade E virus. The serum IgG could also neutralize Thai B (clade B′) strains which possessed a conserved GPGQ motif in their V3 sequences. These data suggest that the rBCG construct secreting the 12aa epitope is implicated in the development of a prophylactic vaccine in Thailand in which both clade E and B′ viruses are prevalent. |
Databáze: | OpenAIRE |
Externí odkaz: |